Genomes and Genes
Andreas S Beutler
Affiliation: Mount Sinai School of Medicine
- Carbamazepine is an inhibitor of histone deacetylasesAndreas S Beutler
Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
Life Sci 76:3107-15. 2005..These observations raise the possibility that HDAC inhibition may contribute to the pharmacological profile of CBZ...
- Intrathecal gene transfer by adeno-associated virus for painAndreas S Beutler
Mount Sinai School of Medicine, Department of Medicine, Division of Hematology Oncology, New York, NY 10029, USA
Curr Opin Mol Ther 7:431-9. 2005..AAV vectors may therefore become an important tool for translational studies to validate newly identified therapeutic targets in clinical pain states...
- Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic painBenjamin Storek
Department of Medicine and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA
Proc Natl Acad Sci U S A 105:1055-60. 2008..Therefore, gene transfer by LP may be suitable for developing gene therapy-based treatments for chronic pain...
- The ZNF217 oncogene is a candidate organizer of repressive histone modifiersMichaela S Banck
Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
Epigenetics 4:100-6. 2009..Taken together, these findings suggest that ZNF217 assembles a distinct set of histone modifying proteins at target DNA sites that act synergistically in transcriptional repression...
- Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in ratsBenjamin Storek
Department of Medicine Hematology Oncology, Mount Sinai School of Medicine, New York, NY, USA
Mol Pain 2:4. 2006..Our studies focused on recombinant adeno-associated virus (rAAV), one of the most promising vector types for clinical use...
- Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinomaJonathan D Schwartz
Mount Sinai School of Medicine, New York, NY 10029, USA
Anticancer Drugs 15:439-52. 2004..More adequately powered, rigorously conducted studies will hopefully identify useful chemo-, radio-, immuno-, embolization-based and biologically targeted therapies during the next decade...
- KLF6 degradation after apoptotic DNA damageMichaela S Banck
Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
FEBS Lett 580:6981-6. 2006..KLF6 was unchanged by apoptosis via the extrinsic/death-receptor pathway. Deregulation of KLF6 stability may alter its tumor suppressor function and/or the response of tumors to chemotherapeutics...